Treating preschooler behavioural sleep problems via parent-mediated telehealth: A randomized controlled trial.

Br J Clin PsycholJun 19, 2025 (epub)
Clinical ResearchPediatricsPsychiatryOpen access

Amy Shiels, Lara J Farrell, Caroline L Donovan

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated a parent-mediated behavioural sleep intervention delivered through three fortnightly 90-minute videoconference sessions for children aged 3–5 years. Parents were allocated to Lights Out Videoconference (LOV; n=19) or care as usual (CAU; n=16), with child sleep problems, anxiety and nighttime fears assessed before treatment, two weeks afterward and at three-month follow-up. Compared with CAU, LOV was associated with significantly greater reductions in all three outcomes from baseline to post-treatment, and these effects were maintained at follow-up. Parent satisfaction with the programme, resources and delivery was very high.

Key findings

  • Compared with care as usual (n=16), LOV (n=19) produced significantly greater reductions in child sleep problems, anxiety and nighttime fears from baseline to post-treatment.
  • Improvements in sleep problems, anxiety and nighttime fears were maintained at the three-month follow-up.
  • Parent satisfaction with the intervention, its resources and videoconference delivery was very high.

Why it matters

Behavioural sleep difficulties in preschool children can coincide with nighttime fears and anxiety. This small randomized trial suggests that a brief, parent-focused intervention delivered remotely may improve these related outcomes, with benefits persisting to three months. The findings add evidence that synchronous telehealth can be an acceptable way to deliver behavioural sleep support to families of young children.

What to keep in mind

The trial was small, with 35 children across both groups. Sleep diary data were not analysed because of substantial missing data in the care-as-usual group, and trial registration was retrospective.

Source

Published in Br J Clin Psychol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.